Aberdeen, UK – 07 October 2014 – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that Dr. Deborah O’Neil, the Company’s Chief Executive Officer, was named EY UK Health Products & Services Entrepreneur of the Year 2014 at the awards dinner held at The Brewery, London last night, attended by over 600 of the country’s top business leaders.
Dr O’ Neil founded NovaBiotics in 2004 and, over the past ten years, has worked to grow the business into a leading global biotechnology company with two clinical-stage compounds, each with annual earning potential of in excess of $1bn.
Dr O’Neil was given the award in recognition of her work to find cures and to combat resistance to antibiotics. Dr Deborah O’Neil, CEO of NovaBiotics, said: “To be acknowledged by this fantastic programme amongst some of the most successful business leaders in the UK is a great honour. I would like to thank all the NovaBiotics team and our stakeholders for their support both for the company and me personally. Without their collective commitment and efforts over the past ten years, this award would not have been achievable.”
Jim Bishop, EY Scotland senior partner, said: “This is the second year in a row that Scots have won more individual Entrepreneur Of The Year categories than any other region of the UK, highlighting the depth of Scottish entrepreneurial talent and the strength of our programme north of the Border.
“In a year when Scotland-based events have dominated headlines, it’s satisfying to see Scots recognised at UK level for their entrepreneurial qualities and not just their politics or ability to host world-class events.”
The EY Entrepreneur of the Year™ programme is considered the world's most prestigious business award and is held in more than 145 cities and in more than 60 countries worldwide. The Award identifies and celebrates the achievements of the world’s most successful, growing and dynamic businesses, taking into consideration entrepreneurial spirit, innovation, strategic direction, financial performance, national and global impact, and approach to social responsibility.
- ENDS -
About NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. A leading innovator in the anti-infectives space, the Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections.
Further information is available at www.novabiotics.co.uk.
Issued for and on behalf of Novabiotics by Instinctif Partners.
For more information please contact:
NovaBiotics:
Dr. Deborah O’Neil - CEO & CSO
deborah@novabiotics.co.uk
Bryan Bodek - Chairman
bryan@novabiotics.co.uk
+44 (0) 1224 711377
For media enquiries:
Instinctif Partners:
Melanie Toyne Sewell/Gemma Howe/Emma Barlow
novabiotics@instinctif.com
Tel: +44 (0) 20 7457 2020
Help employers find you! Check out all the jobs and post your resume.
Dr O’ Neil founded NovaBiotics in 2004 and, over the past ten years, has worked to grow the business into a leading global biotechnology company with two clinical-stage compounds, each with annual earning potential of in excess of $1bn.
Dr O’Neil was given the award in recognition of her work to find cures and to combat resistance to antibiotics. Dr Deborah O’Neil, CEO of NovaBiotics, said: “To be acknowledged by this fantastic programme amongst some of the most successful business leaders in the UK is a great honour. I would like to thank all the NovaBiotics team and our stakeholders for their support both for the company and me personally. Without their collective commitment and efforts over the past ten years, this award would not have been achievable.”
Jim Bishop, EY Scotland senior partner, said: “This is the second year in a row that Scots have won more individual Entrepreneur Of The Year categories than any other region of the UK, highlighting the depth of Scottish entrepreneurial talent and the strength of our programme north of the Border.
“In a year when Scotland-based events have dominated headlines, it’s satisfying to see Scots recognised at UK level for their entrepreneurial qualities and not just their politics or ability to host world-class events.”
The EY Entrepreneur of the Year™ programme is considered the world's most prestigious business award and is held in more than 145 cities and in more than 60 countries worldwide. The Award identifies and celebrates the achievements of the world’s most successful, growing and dynamic businesses, taking into consideration entrepreneurial spirit, innovation, strategic direction, financial performance, national and global impact, and approach to social responsibility.
- ENDS -
About NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. A leading innovator in the anti-infectives space, the Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections.
Further information is available at www.novabiotics.co.uk.
Issued for and on behalf of Novabiotics by Instinctif Partners.
For more information please contact:
NovaBiotics:
Dr. Deborah O’Neil - CEO & CSO
deborah@novabiotics.co.uk
Bryan Bodek - Chairman
bryan@novabiotics.co.uk
+44 (0) 1224 711377
For media enquiries:
Instinctif Partners:
Melanie Toyne Sewell/Gemma Howe/Emma Barlow
novabiotics@instinctif.com
Tel: +44 (0) 20 7457 2020
Help employers find you! Check out all the jobs and post your resume.
